Pyxis Oncology (PYXS) Net Income towards Common Stockholders (QoQ) (2020 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.65% |
| Sep 30, 2025 | -21.76% |
| Jun 30, 2025 | 16.62% |
| Mar 31, 2025 | 39.07% |
| Dec 31, 2024 | -67.76% |
| Sep 30, 2024 | -22.55% |
| Jun 30, 2024 | -223.81% |
| Mar 31, 2024 | 66.96% |
| Dec 31, 2023 | 31.61% |
| Sep 30, 2023 | -43.62% |
| Jun 30, 2023 | 17.21% |
| Mar 31, 2023 | 44.91% |
| Dec 31, 2022 | -30.45% |
| Sep 30, 2022 | -8.26% |
| Jun 30, 2022 | 18.54% |
| Mar 31, 2022 | -91.12% |
| Dec 31, 2021 | -41.36% |
| Sep 30, 2021 | -95.70% |
| Jun 30, 2021 | 83.39% |
| Mar 31, 2021 | -680.19% |
| Dec 31, 2020 | -43.50% |